IQWiG rejects Astellas's Betmiga for overactive bladder
This article was originally published in Scrip
Executive Summary
Germany's health technology appraisal (HTA) body, IQWiG, has said that Astellas's overactive bladder drug Betmiga (mirabegron) shows no additional benefit over comparators.